
ADC Therapeutics SA ADCT
$ 3.94
-0.51%
Annual report 2022
added 12-21-2024
ADC Therapeutics SA Deferred Revenue 2011-2026 | ADCT
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue ADC Therapeutics SA
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 834 K | 1.76 M | 2.32 M | 1.84 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.32 M | 834 K | 1.69 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M | ||
|
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | ||
|
I-Mab
IMAB
|
563 K | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M | ||
|
AIkido Pharma
AIKI
|
957 K | - | 1.93 % | $ 17.4 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
2.51 M | - | -19.68 % | $ 18.4 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
124 K | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
2.64 M | $ 21.96 | -0.68 % | $ 3.64 B | ||
|
RedHill Biopharma Ltd.
RDHL
|
19.5 M | $ 1.02 | -0.49 % | $ 428 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
165 K | - | -9.65 % | $ 45.9 M | ||
|
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
85.7 K | - | -11.43 % | $ 502 K | ||
|
Aligos Therapeutics
ALGS
|
151 K | $ 6.4 | 4.4 % | $ 63.3 M | ||
|
Applied Therapeutics
APLT
|
667 K | - | - | $ 8.42 M | ||
|
Aridis Pharmaceuticals
ARDS
|
20.2 M | - | 17.91 % | $ 11.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
643 K | $ 21.41 | 1.9 % | $ 1 B | ||
|
Aravive
ARAV
|
4.41 M | - | -13.39 % | $ 1.45 M | ||
|
BioDelivery Sciences International
BDSI
|
1.72 M | - | -4.8 % | $ 255 M | ||
|
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
2.62 M | - | -2.5 % | $ 5.88 M | ||
|
Kazia Therapeutics Limited
KZIA
|
138 K | $ 12.26 | 3.72 % | $ 1.62 B | ||
|
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
300 M | $ 105.46 | -0.09 % | $ 27.2 B | ||
|
BeiGene, Ltd.
BGNE
|
187 M | - | 0.49 % | $ 251 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
6.3 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
1.09 M | $ 4.08 | 0.25 % | $ 436 M | ||
|
Cara Therapeutics
CARA
|
22.3 M | - | -3.03 % | $ 260 M | ||
|
CASI Pharmaceuticals
CASI
|
2.35 M | - | - | $ 35.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 2.91 | -1.36 % | $ 4.79 M | ||
|
bluebird bio
BLUE
|
2.28 M | - | - | $ 546 M | ||
|
CymaBay Therapeutics
CBAY
|
1.69 M | - | - | $ 3.45 B |